The most recent company to join MEDX Xelerator, Append Medical, develops a minimally invasive solution designed to prevent stroke in patients suffering from atrial fibrillation.

Append’s solution includes an implantable device for excluding the left atrial appendage (LAA), which generates 90% of thrombus in atrial fibrillation (AF) patients, thus exposing AF patients to increased risk of stroke. Atrial fibrillation is a health problem affecting millions of people across the globe. Append’s mission is to develop the next generation LAA exclusion device, one which can be easily implanted while minimizing complications.

“We are delighted to have Append join MEDX Xelerator and believe the company will make a significant contribution to solving this large and growing problem,” said Shai Policker, MEDX Xelerator’s CEO.

Append’s technology for LAA exclusion was invented by Dr. Leonid Sternik and developed in Sheba Medical Center, from which Append licensed it.

“There are millions of people worldwide who have reasons to seek alternatives to currently-available stroke-prevention treatments for patients with non-valvular atrial fibrillation,” added Append’s founder and CEO, Zachi Berger, PhD, MBA, a seasoned executive in the healthcare field, with over 30 years of experience as an entrepreneur, a manager and a VC investor. “With the support of MEDX Xelerator and its partners, such as Boston Scientific, a leader in interventional cardiology innovation, Append can give those millions of people a new hope.”

Before founding Append, Zachi Berger established four companies with one exit (XTL, Peptor, Quantomix, Endopix) and as a VC investor in Star Ventures he led investments in five companies with exits.

 

About MEDX Xelerator:

MEDX Xelerator is a MedTech incubator located in Or Yehuda, Israel, specializing in seed-stage medical technologies for minimally invasive procedures, medical robotics and implantables. Its partners are Boston Scientific, Intellectual Ventures, MEDX Ventures Group and Sheba Medical Center.